A pilot randomized controlled trial of de novo belatacept‐based immunosuppression following anti‐thymocyte globulin induction in lung transplantation

The development of donor‐specific antibodies (DSA) after lung transplantation is common and results in adverse outcomes. In kidney transplantation, Belatacept has been associated with a lower incidence of DSA, but experience with Belatacept in lung transplantation is limited. We conducted a two‐cent...

Ausführliche Beschreibung